Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced melanoma who had stopped responding to standard immunotherapy. The findings mark a major milestone for the Halifax-based nanotechnology company as it transitions from preclinical research to clinical development. Proactive spoke with David Regan, CEO of Sona Nanotech, to discuss the study results, how the therapy ...

Core Insights - Sona Nanotech Inc. reported an 80% response rate in its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for treating immunotherapy-resistant cutaneous metastatic melanoma, with six out of ten patients achieving complete responses and two showing partial responses within two weeks of treatment [1][2] Group 1: Clinical Study Results - The study involved ten advanced-stage melanoma patients who were not responding to standard immunotherapy, with eight patients showing significant clinical responses by day 15 [1][2] - Six out of the eight responding patients had no detectable residual melanoma in biopsied tumors, while two patients did not respond [1][2] - The rapid response observed in patients has provided meaningful hope for those who had exhausted standard treatment options [2] Group 2: Future Plans and Development - Based on the study findings, the company is preparing for a Canadian clinical trial to explore the biological potential of THT in a broader range of solid tumors, with an application for investigational testing authorization submitted to Health Canada [2] - The company aims to enhance the design and application of THT based on clinician-reported and patient-reported experiences captured during the study [2] Group 3: Safety and Tolerability - Safety data indicated favorable results, with one serious adverse event deemed unrelated to THT and resolved, while two patients expired due to disease progression [2] - The study's outcomes validate earlier preclinical findings and provide compelling evidence of THT's efficacy and tolerability in human cancer treatment [2][3] Group 4: Company Background - Sona Nanotech is focused on developing Targeted Hyperthermia, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, aiming to stimulate the immune system and improve drug delivery to tumors [4][5]

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients ...

Core Viewpoint - Sona Nanotech Inc. has received approval to conduct a pilot clinical trial for its Targeted Hyperthermia Therapy (THT) aimed at treating late-stage melanoma patients, marking a significant step towards clinical application of its innovative cancer treatment technology [1][2]. Group 1: Clinical Trial Details - The pilot study will involve 30-40 patients and is contingent upon obtaining Investigational Testing Authorization from Health Canada [1][2]. - The anticipated start date for the pilot study is late 2025 or early 2026 [2]. Group 2: Company Background and Technology - Sona Nanotech is focused on developing Targeted Hyperthermia™, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, enhancing drug delivery and immune response [3]. - The therapy involves heating tumors to a range of 42-48°C using infrared light absorbed by gold nanorods, which are designed to be safe and effective [3]. - The company has developed proprietary methods for manufacturing gold nanoparticles that are free from cetyltrimethylammonium (CTAB), reducing toxicity risks associated with other technologies [4]. Group 3: Market Context - Melanoma cases in Canada have tripled over the past 30 years, with over 1,300 deaths annually, highlighting the urgent need for effective treatments [2].